MedTrace Logo

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

NCT07211659 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-22

No results posted yet for this study

Summary

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Conditions

Interventions

BIOLOGICAL

THEO-260

Oncolytic virus

Sponsors & Collaborators

  • Theolytics Limited

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Theolytics Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-13
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211659 on ClinicalTrials.gov